NCT06634940 International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections
| NCT ID | NCT06634940 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Italiano de Buenos Aires |
| Condition | Cirrhosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-11-15 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-11-15 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
What is this study about? This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections. Why is this study important? Bacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospitalized. These infections can be life-threatening, with 1 in 4 patients dying from complications. Many of these infections are becoming harder to treat because the bacteria are resistant to antibiotics. Infections caused by resistant bacteria are increasing, which makes finding the right antibiotic quickly even more difficult. In other regions of the world, guidelines exist to help doctors choose the right antibiotics for cirrhosis patients. However, in Latin America, we don't have specific guidelines for our region, and doctors currently rely on recommendations from the U.S. or Europe. These guidelines may not reflect the local patterns of bacterial infections and resistance we see here. What is the goal of this study? The main goal of this study is to create a long-term system to track how bacteria respond to antibiotics in patients with cirrhosis in Latin America. By collecting data from hospitals across different countries, we aim to: * Identify how many infections are caused by multidrug-resistant bacteria. * Understand how antibiotics (such as ceftriaxone, vancomycin, and carbapenems) act against these infections. * Generate reports informing bacterial resistance patterns to help doctors make better patient treatment decisions. What do we hope to achieve? We hope the data we collect will help develop guidelines for patients with cirrhosis in Latin America. These guidelines will ensure that doctors use the most effective antibiotics based on real-time data from our region. This should improve patient outcomes and help prevent the spread of resistant bacteria.
Eligibility Criteria
Inclusion Criteria: * Episodes of culture-confirmed bacterial infections * Patients diagnosed with cirrhosis * Infections diagnosed either at the time of hospital admission or during hospitalization Exclusion Criteria: * History of solid organ or hematopoietic stem cell transplantation * Declined to participate in the study
Contact & Investigator
Sebastián M Marciano, Principal Investigator.
✉ sebastian.marciano@hospitalitaliano.org.ar📞 54 11 49590200
Frequently Asked Questions
Who can join the NCT06634940 clinical trial?
This trial is open to participants of all sexes, aged 17 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06634940 currently recruiting?
Yes, NCT06634940 is actively recruiting participants. Contact the research team at sebastian.marciano@hospitalitaliano.org.ar for enrollment information.
Where is the NCT06634940 trial being conducted?
This trial is being conducted at Buenos Aires, Argentina.
Who is sponsoring the NCT06634940 clinical trial?
NCT06634940 is sponsored by Hospital Italiano de Buenos Aires. The trial plans to enroll 1,000 participants.